Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELOX-Trastuzumab in Resectable Gastric Cancer
NCT01130337Phase 2Completed
- Sponsor
- Roche
- Start
- Jul 2010
- Primary completion
- Jun 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Roche. Started Jul 2010; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT01130337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01130337.